Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Mayo Clin Proc. 2015 Jan;90(1):35–42. doi: 10.1016/j.mayocp.2014.10.005

Figure 1.

Figure 1

Relative concentrations (normalized to urine creatinine concentration) of AQP1 (A) and PLIN2 (B) in the urine of patients with clear cell and papillary kidney cancers, all 26 control patients, and patients with an angiomyolipomas, chromophobe kidney cancer or an oncocytoma. Box plots show the median along with the 1st and 3rd quartile. (+) outlier > 1.5 and < 3 of the interquartile range. (*) outlier > 3 of the interquartile range. The median urine AQP1 and PLIN2 concentrations are significantly greater in RCC patients compared to the controls or other patient groups (P<0.001 for both, Kruskal-Wallis test with Bonferroni correction). The median and 1st/3rd quartile for urine PLIN2 of patients with an angiomyolipoma were significantly greater than that of controls (P<.001) or patients with oncocytoma (P<.001) (Kruskal-Wallis test). The insert shows ROC plots comparing the AQP1 or PLIN2 concentrations of the patients with RCC to that of all patients with AMLs, chromophobes and oncocytomas. The area under the ROC curves are 1.00 for Figures 1A and 0.99 for Figure 1B.